This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (7)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In generalized cases, bullous pemphigoid (BP) requires treatment with oral systemic corticosteroids, l mg/kg per day, prednisone or prednisolone. Despite oral steroids, BP is not controlled in about 30% of patients treated with prednisolone metasulfobenzoate (PO-MS), 1 mg/kg per day.^1-2 Prednisolone is the active molecule accounting for the anti-inflammatory activity in vivo after oral intake of prednisone or PO-MS. Some cases of clinical resistance in patients treated for inflammatory diseases have been observed following the administration of PO-MS, which were reversed using prednisone in the same mole-per-liter dose. Pharmacokinetic studies in healthy subjects showed higher availability of prednisolone after administration of prednisone than after PO-MS because of better intestinal absorption of prednisone.^3-5 The aim of this retrospective study was to determine if prednisone if more efficacious than PO-MS for the initial control of BP.

Patients and Methods

Patients were included in the study if the following 2 criteria were fulfilled: (1) a diagnosis . . . [Full Text of this Article]

Results

Comment


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

A Comparison of Oral and Topical Corticosteroids in Patients with Bullous Pemphigoid
Joly et al.
NEJM 2002;346:321-327.
ABSTRACT | FULL TEXT